Floatz logo

CIS-DIAMMINEDICHLOROPLATINUM II

Immunoproliferative Disorders

Fudan UniversitySmall moleculePhase 2Dormant
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

12 Active assets in the Immunoproliferative Disorders cohort.

Asset / SponsorPhaseRating
Zilovertamab
Oncternal Therapeutics, Inc
Phase 3B
Ibrutinib
Oncternal Therapeutics, Inc
Phase 3B
Jcar017 (Lisocabtagene Maraleucel)
Juno Therapeutics, a Subsidiary of Celgene
Phase 2B
Chimeric Antigen Receptor Modified T Cells Infusion
UNC Lineberger Comprehensive Cancer Center
Phase 1/2CCC
Tucidinostat
Fudan University
Phase 2CCC

View all 17 →

Same molecule, other indications

CIS-DIAMMINEDICHLOROPLATINUM II is also rated in:

squamous cell lung carcinomaDormant
BBB
Indicative ·
78 / 100
View asset →
primary peritoneal carcinomaDormant
BBB
Indicative ·
77 / 100
View asset →
adenocarcinomaDormant
BBB
Indicative ·
76 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →